Medi Whale's AI screening platform solution, Reti-Intelligence, utilizes deep learning algorithms to assess cardiovascular, renal, metabolic risk, and eye diseases. Their retinal biomarker engines, RetiCVD, RetiCKD, and RetiEYE, provide accurate risk assessment for cardiovascular disease, chronic kidney disease, and common aging-related eye diseases. Medi Whale's technology has been clinically proven to be effective and is recognized by the clinical and scientific communities. With product approvals in multiple territories, including Europe, Asia, and pending FDA approval, Medi Whale aims to make preventative care more accessible and affordable.